

Nasdaq: ANGN

INVESTOR FACT SHEET

Angeion Corporation

Fourth Quarter 2007

Profile

Angeion Corporation, through its subsidiary Medical Graphics Corporation, designs, manufactures and distributes non-invasive cardiorespiratory diagnostic systems for medical and fitness management purposes.



MEDGRAPHICS™
Cardiorespiratory Diagnostics

Medical Graphics' patented technology has been used

by heart and lung specialists for nearly 30 years in the diagnosis and treatment of asthma, emphysema, congestive heart failure and other conditions. These products are sold internationally through distributors and in the United States through a direct sales force that targets hospitals, clinics and physicians' offices.



New Leaf

New Leaf health and fitness products, many derived from Medical

Graphics core technologies, help consumers improve fitness and manage weight. Today, New Leaf products are marketed primarily to health and fitness centers through a direct sales force. These products provide a roadmap for consumers to achieve their goals through personalized exercise and nutrition plans based on their measured resting and exercise metabolism.




MEDGRAPHICS™
Cardiorespiratory Diagnostics
CLINICAL RESEARCH

Medical Graphics also provides systems for clinical research to test the


efficacy and safety of new drugs by measuring cardiopulmonary function. Target customers for these MedGraphic systems are pharmaceutical companies and contract research organizations (CROs). Medical Graphics supports clinical trials through data acquisition and workflow management as well as service, support and education at over 65 global support locations.

There are currently more than 8,000 installed MedGraphics and New Leaf systems in active use in more than 60 countries around the world.



MedGraphics new CCM Express

Annual Revenue History



Financial Highlights (Nasdaq: ANGN)

For the Quarter Ended October 31, 2007

Revenue:	\$9.1 million
Net Income:	\$111,000

At October 31, 2007

Shares Outstanding	4.1 million
Cash	\$6.9 million
Shareholders' Equity	\$17.4 million

Stock Price Information

Closing price 2/26/08	\$8.24
90 Day Low/high	\$5.95 - \$9.77
Average Trading Volume	35,579
Market Cap	\$33.8 million
Price/Revenues	0.9
Price/EBITDA	12.2
Price/Earnings	34.4
Price/Book	1.9



New Leaf Exercise Assessment

Recent Results

In the fourth quarter ended October 31, 2007, Angeion reported net income of \$111,000, or \$0.03 per diluted share, on revenues of \$9.1 million. This compares to net income of \$755,000, or \$0.20 per diluted share, on revenues of \$10.7 million in the fourth quarter of last year. The Company reported that its gross margin improved to 51.9% in the fourth quarter of fiscal 2007, up from 49.2% in the same quarter last year, as a result of manufacturing efficiencies and improved product mix.

For the fiscal year ended October 31, 2007, Angeion reported revenues of \$38.6 million, up 14.6%, from revenues of \$33.7 million a year ago. Net income for fiscal 2007 was \$1.1 million or \$0.24 per diluted share, versus \$1.4 million, or \$0.38 per diluted share last year. Net income for fiscal 2006 included a gain from discontinued operations of \$171,000 or \$0.04 per diluted share.


2007 Accomplishments:

- Fifth consecutive year of double-digit revenue growth
- Successful Q4 launch of CCM Express® nutritional measurement device for hospital intensive care units
- Agreement with strategic partner, Garmin International, which enables integration of Angeion's New Leaf Active Metabolic Training™ with Garmin's Forerunner 305 GPS fitness device, and
- New representative branch office in Milan, Italy


Sales to Angeion's large clinical reserach customer accounted for 8.7% of revenues in the fourth quarter of 2007 versus 34.7% in the fourth quarter of 2006. Excluding sales to this customer, revenue for the fourth quarter of 2007 increased by 19.3% over the fourth quarter of 2006 and 24.1% for the year. The Company expects revenues from clinical research to continue throughout fiscal 2008 but at a reduced level due to this customer's unanticipated early conclusion of their clinical trial.

Angeion's New Leaf brand of products saw an increase of 40% in sales of client assessment packs and helped drive margin improvements for the year.

Q4 Revenue 2005-2007



Q4 Net Income 2005-2007



Looking Ahead in 2008

Our top priority is to execute our strategy to grow profitably by:

- Introducing new products in our cardiopulmonary diagnostic and weight management product lines
- Implementing physician-office programs targeting chronic pulmonary disease
- Entering select new markets
- Gaining market share in the cardiorespiratory and commercial fitness market
- Enhancing our international distribution channel
- Pursuing new clients in the clinical research arena.

Corporate Information

Angeion Corporation

350 Oak Grove Parkway
 Saint Paul, MN 55127-8599

Phone: 651-484-4874
 Fax: 651-484-4826
 Web Site: www.angeion.com
 Web Site: www.medgraphics.com
 Web Site: www.newleaffitness.com
 Email: investor@angeion.com